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In this issue of the British Journal of Cancer, Brammer and co-
workers investigate the status of endostatin expression in human
pancreas cancer and normal pancreatic tissue. Endostatin was
originally identified from the conditioned media of glioendothe-
lioma cells as an inhibitor of angiogenesis (O’Reilly et al, 1997).
These antiangiogenic properties immediately excited interest in
the potential of endostatin as a modifier of cancer biology.
Endostatin is derived as a proteolytic cleavage product from the C-
terminus of the alpha chain of collagen XVIII, an extracellular
matrix protein multiplexin (triple helix collagenous domain
protein) encoded on human chromosome 21q22.3. Mutations of
this region give rise to Knobloch syndrome, which is characterised
by aberrant ocular development ascribed in part to a failure of
regression blood vessels in the vitreous after birth and a failure of
development of the retinal vasculature (Fukai et al, 2002).
In cancer biology, it has been demonstrated that endostatin can
not only prevent the angiogenic switch early in tumour develop-
ment but can also induce regression of some established tumours
(Bergers et al, 1999). The same study also showed that the efficacy
of endostatin in altering tumour vascularity could be potentiated
by coadministration of other inhibitors of angiogenesis such as
angiostatin. The mechanism of endostatin activity is still being
elucidated; however, it seems likely that its effect may be mediated
through more than one pathway (Abdollahi et al, 2004) and may
also require the presence of other moieties such as e-selectin (Yu
et al, 2004).
In a SCID mouse xenograft model, the human pancreatic
carcinoma Hs-776T HS-W variant, which expresses endostatin,
grows more slowly than the HS-R variant, which does not (Schuch
et al, 2002). In the Hs-776 cell line, overexpression of vascular
endothelial growth factor can overcome the inhibitory effect of
endostatin on tumour growth, thus it seems likely that in this
model, tumour growth is related to the balance between pro- and
antiangiogenic factors. In another pancreas cancer xenograft
model, rapidly growing L3.6pl tumours and slower growing BxPC3
were established in the peritoneal cavities of athymic nude mice,
which were then treated with recombinant human endostatin
(Raut et al, 2004). Endostatin resulted in reduced interleukin-8
expression in the animals and increased apoptosis rates in the
L3.6pl tumours, but the actual tumour burden in terms of
peritoneal carcinomatosis was increased compared with vehicle
controls. Endostatin had less effect on the slower growing BxPC3
tumour. It is known that different xenograft models are regulated
by different pathways, and that the necessary absence of a fully
functional immune system in the host will also make these models
somewhat artificial. It is clear however that endostatin can exert
quite profound effects on xenografted human pancreas cancers
and future work may improve our understanding of the scope and
limitation of its use.
Brammer and co-workers found that endostatin was detectable
in homogenates of resected human pancreatic cancers but not
normal pancreas, and went on to demonstrate that in healthy
pancreas endostatin is degraded by elastase but that the low or
absent expression of elastase in pancreatic cancers is associated
with stable endostatin expression. They hypothesise that the
expression of endostatin in pancreatic tissues may in part explain
the relatively avascular nature of these tumours. This relationship
between the cancer and the inflammatory and stromal tissue
surrounding it may therefore determine its biological behaviour. It
seems counter-intuitive that a tumour should secrete an inhibitor
of angiogenesis and the survival advantage of such a strategy is not
immediately obvious. While we understand that an important part
of the process of cancer invasion and metastasis requires
angiogenesis, it is still possible that expression of an inhibitor of
angiogenesis in an established tumour may be beneficial to the
tumour. For example, tumours with poor vascularity may escape
immunosurveillance to a greater degree than more vascular
tumours and it is possible that the relatively poor response rates
of pancreas cancers to conventional chemotherapy may also be
associated with their avascular nature. Alternatively, chemother-
apy may place a selection pressure on cancer cells selecting out
clones, which by virtue of their inability to express elastase and
break down endostatin, become relatively avascular. Such philo-
sophy implies that a cancer attempts willingly or unwillingly to
establish a survival benefit. This may be far too complex and the
explanation may be much more straightforward. Expression of
endostatin may simply arise as a consequence of the failure of
pancreatic cancers to express the degradative enzyme elastase.
Since endostatin inhibits angiogenesis, it is interesting to
speculate what the consequence would be if it were not present.
Presumably, the tumour would have a more aggressive phenotype
and it is not yet clear whether all pancreatic tumours do not
express elastase or whether elastase expression may in some way
determine pancreatic cancer behaviour through its effects on
endostatin stability and expression. Perhaps, it is the balance
between the expression of endostatin and elastase that is important
in determining the phenotype of pancreas cancers. Whether
surgical removal of a pancreas cancer also removes the inhibitory
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this might be most evident in an adjuvant surgical model. In this
context, the benefits of an angiogenesis inhibitor in preventing
tumour metastasis would have to be balanced with the risks of
potentially delaying wound healing.
The relative instability of endostatin may limit its usefulness as a
cancer treatment; however, it has been documented that contin-
uous infusion can improve its efficacy over bolus treatment
(Kisker et al, 2001). Now that at least one inhibitor of endostatin is
known, it may also be possible to modify the amino-acid sequence
of endostatin to create analogues, which retain antiangiogenic
activity but which are more resistant to degradation by pancreatic
elastase. One issue which was not addressed by the study by
Brammer et al (2005) is whether any products of endostatin
resulting from elastase digestion retain activity as inhibitors of
angiogenesis. Adenocarcinoma of the pancreas has largely
frustrated the efforts of oncologists to modify its behaviour. The
failure of pancreatic cancers to elaborate elastase and the
consequent inability to degrade the angiogenesis inhibitor
endostatin may represent a chink in the armour of pancreas
cancer upon which an effective treatment regimen can be
designed.
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